ScholarWorks@SUNGKYUNKWAN UNIVERSITY: PYO, HONG RYULL

Detailed Information

PYO, HONG RYULL (표홍렬)

Medicine (Medicine)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Radiotherapy:11||nonsmall cell lung cancer:9||Nonsmall cell lung cancer:7||Radiation therapy:6||Nonsmall cell lung carcinoma:6||Proton beam therapy:6||Lung cancer:4||radiotherapy:4||Nonsmallcell lung cancer:3||Intensitymodulated radiotherapy:3||Stage IIIA:3||Proton therapy:3||lung cancer:3||Trimodality therapy:2||chemoradiotherapy:2||Magnetic resonance imaging:2||prognosis:2||Nonsmallcell lung carcinoma:2||Celecoxib:2||small cell lung cancer:2||Prostate cancer:2||Helical tomotherapy:2||Concurrent chemoradiotherapy:2||Idiopathic pulmonary fibrosis:2||Lung neoplasms:2||NSCLC:2||Neoadjuvant concurrent chemoradiotherapy:2||SBRT:2||Neoadjuvant therapy:2||Locoregional recurrence:2||Surgery:2||Chemotherapy:2||Prostatectomy:2||proton beam therapy:2||COX2:2||radiation therapy:2||Keywords: Proton therapy:1||LASSO score:1||Lateral penumbra:1||Line scanning:1||Liquid biopsy:1||Lobectomy:1||Locoregional recurrence:1||Locoregional neoplasm recurrence:1||Lymph node:1||Lymph node metastasis:1||Lymphopenia:1||Monte Carlo:1||Multileaf collimator:1||N2:1||N2 disease:1||Neoplasm metastasis:1||Nephrectomy:1||Neutron dose:1||Nivolumab:1||Non small cell lung cancer:1||Nonsmall cell lung cancer (NSCLC):1||Nonsmall cell lung cancer with N2 disease:1||Nonsquamous nonsmall cell lung cancer:1||Nontuberculous mycobacteria:1||Particle accelerator:1||Patterns of failure:1||Patterns of locoregional recurrence:1||Pencil beam scanning:1||Persistent N2:1||Photon:1||Postoperative radiation therapy:1||Prognostic factor:1||Prostate neoplasm:1||Prostatic neoplasms:1||Proton:1||Radiation:1||Radiation oncology:1||Radiation pneumonitis:1||Radiationinduced complication:1||Radiosensitization:1||Radiosurgery:1||Radiotherapy dosage:1||Reirradiation:1||Recurrence:1||Renal cell carcinoma:1||Risk factors:1||Salvage concurrent chemoradiation therapy:1||Salvage therapy:1||Small cell lung carcinoma:1||Spinal neoplasms:1||Stage III:1||Stage IIIAN2:1||Stage IIIBN3:1||Supportive care:1||Survival:1||Synthetic computed tomography:1||Thymic tumor:1||Tomotherapy:1||Tuberculosis:1||UCN01:1||Unsuspected N2 lymph node:1||Urinary bladder neoplasms:1||Urothelial carcinoma:1||18 FFDG PET/CT:1||YAP1:1||adenocarcinoma:1||aged:1||blood:1||cDNAmicroarray:1||carcinoma:1||celecoxib:1||cell cycle:1||chemoradiation:1||complication:1||concurrent chemoradiotherapy:1||cyclooxygenase2:1||decision curve analysis:1||dosimetric comparison:1||earlystage lung cancer:1||esophageal cancer:1||great vessel invasion:1||histologic type:1||hypofractionated radiation therapy:1||hypofractionated radiotherapy:1||inflammation:1||intensity modulated proton therapy:1||intensity modulated radation therapy:1||intratumoral heterogeneity:1||locoregional r:1||lymphopenia:1||machine learning:1||metabolic tumor volume:1||molecular subtype:1||neoadjuvant CCRT:1||neoadjuvant chemoradiotherapy:1||neoadjuvant concurrent chemoradiotherapy:1||nonsmall cell lung cancer (NSCLC):1||nonsmall cell lung carcinoma:1||nutrition:1||outcomes:1||overall survival:1||pathologic complete response:1||pattern of failure:1||pattern of recurrence:1||photon beam:1||prognostic biomarker:1||prognostic factor:1||prophylactic cranial irradiation:1||prostate cancer:1||prostate specific antigen:1||proton beam:1||pulmonary disease:1||pulmonary function test:1||pulmonary toxicity:1||radiomics:1||random forest:1||recurrence:1||recurrence dynamics:1||salvage:1||sarcopenia:1||siRNA:1||skeletal muscle loss:1||smallcell lung cancer:1||stereotactic ablative radiotherapy:1||stereotactic body radiation therapy:1||stereotactic body radiotherapy:1||supraclavicular lymph node metastasis:1||surgery:1||survival:1||target volume:1||thymic epithelial tumor:1||total lesion glycolysis:1||tumor regression:1||Videoassisted thoracoscopic surgery:1||Adjuvant chemotherapy:1||Adjuvant concurrent chemoradiotherapy:1||Adjuvant radiotherapy:1||Aspergillosis:1||Biochemical failurefree survival:1||Bulky nodal involvement:1||Cellfree DNA:1||Cen:1||Central tumors:1||Chemoradiation:1||Chemoradiotherapy:1||Chk1:1||Chronic obstructive pulmonary disease (COPD):1||Chronic pulmonary infection:1||Clinical target volume:1||Complication:1||Concurrent chemoradiation therapy:1||Concurrent chemoradiotherapy:1||Consolidation:1||Deep learning:1||Diseasespecific survival:1||Dose fractionation:1||Durvalumab:1||Dynamics:1||EGFR mutation:1||Extensivestage:1||F18FDG PET/CT:1||FDG PET/CT:1||Fractures, compression:1||I:1||Immunotherapy:1||Intensitymodulated radiation therapy:1||Interstitial lung disease:1||Invasive mediastinal nodal staging:1||Ionizing radiation:1||

STATISTICS: Total View :5,228,115; Today View :2

RSS_1.0 RSS_2.0 ATOM_1.0

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREAsamsunglib@skku.edu

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE